Tezepelumab for severe asthma: PATHWAY and NAVIGATOR studies

In this animated video article, we present the findings of two clinical trials that investigated the safety and efficacy of tezepelumab for severe asthma, the PATHWAY and NAVIGATOR studies.

Asthma attacks are triggered by breathing in particles in the air, such as allergens, viruses, or bacteria which irritate the airways. This causes a protein called thymic stromal lymphopoietin (TSLP) to be released – TSLP production is one of the first steps in the airway inflammation pathway leading to an asthma attack.

Tezepelumab is a drug that blocks the action of TSLP. By blocking a key first step in this inflammation pathway, it is hoped that the drug will have a broader effect that other severe asthma treatments.

The phase II PATHWAY and phase III NAVIGATOR clinical studies assessed the use of tezepelumab for people with severe, uncontrolled asthma.

Clinical Trial Registration: PATHWAY study: NCT02054130 (ClinicalTrials.gov); NAVIGATOR Study: NCT03347279 (ClinicalTrials.gov)

Original articles:

Menzies-Gow A, Corren J, Bourdin A et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384:1800-1809. DOI: 10.1056/NEJMoa2034975

Corren J, Parnes JR. Wang L et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377:936-46. DOI: 10.1056/NEJMoa1704064

Click the link below to read the Plain Language Summary of Publication (PSLP) presenting the PATHWAY and NAVIGATOR studies.